ClariVest Asset Management LLC increased its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.1% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 282,265 shares of the company’s stock after buying an additional 308 shares during the period. Thermo Fisher Scientific comprises about 1.2% of ClariVest Asset Management LLC’s investment portfolio, making the stock its 24th largest position. ClariVest Asset Management LLC’s holdings in Thermo Fisher Scientific were worth $41,707,000 as of its most recent SEC filing.
A number of other large investors also recently added to or reduced their stakes in the stock. Bank of Montreal Can bought a new stake in Thermo Fisher Scientific during the second quarter worth $32,053,000. Carmignac Gestion increased its stake in Thermo Fisher Scientific by 23.3% in the second quarter. Carmignac Gestion now owns 4,046,550 shares of the company’s stock worth $597,918,000 after buying an additional 763,421 shares during the last quarter. Bellevue Group AG bought a new stake in Thermo Fisher Scientific during the first quarter worth $2,832,000. Artemis Investment Management LLP increased its stake in Thermo Fisher Scientific by 54.6% in the second quarter. Artemis Investment Management LLP now owns 172,789 shares of the company’s stock worth $25,530,000 after buying an additional 61,046 shares during the last quarter. Finally, Puplava Financial Services Inc. increased its stake in Thermo Fisher Scientific by 0.8% in the second quarter. Puplava Financial Services Inc. now owns 8,819 shares of the company’s stock worth $1,303,000 after buying an additional 71 shares during the last quarter. 87.38% of the stock is currently owned by institutional investors.
Shares of Thermo Fisher Scientific Inc. (NYSE:TMO) traded up 0.45% during trading on Wednesday, reaching $158.28. 1,165,431 shares of the company were exchanged. The stock’s 50-day moving average is $152.98 and its 200-day moving average is $150.30. The firm has a market cap of $62.40 billion, a price-to-earnings ratio of 31.66 and a beta of 0.97. Thermo Fisher Scientific Inc. has a 52-week low of $119.75 and a 52-week high of $160.68.
Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Thursday, July 28th. The company reported $2.03 earnings per share for the quarter, beating analysts’ consensus estimates of $2.01 by $0.02. Thermo Fisher Scientific had a net margin of 11.35% and a return on equity of 14.70%. The firm had revenue of $4.54 billion for the quarter, compared to analyst estimates of $4.50 billion. During the same quarter last year, the business posted $1.84 earnings per share. The company’s quarterly revenue was up 6.2% on a year-over-year basis. Equities research analysts predict that Thermo Fisher Scientific Inc. will post $8.17 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Monday, October 17th. Stockholders of record on Thursday, September 15th will be issued a dividend of $0.15 per share. The ex-dividend date is Tuesday, September 13th. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.38%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 12.02%.
Several brokerages have recently commented on TMO. Cleveland Research downgraded Thermo Fisher Scientific from a “buy” rating to a “neutral” rating in a report on Friday, September 9th. JPMorgan Chase & Co. began coverage on Thermo Fisher Scientific in a report on Thursday, September 22nd. They issued an “overweight” rating and a $180.00 target price on the stock. Zacks Investment Research raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $175.00 target price on the stock in a report on Wednesday, July 20th. Citigroup Inc. boosted their target price on Thermo Fisher Scientific from $160.00 to $182.00 and gave the stock a “buy” rating in a report on Friday, July 29th. Finally, Mizuho set a $175.00 target price on Thermo Fisher Scientific and gave the stock a “buy” rating in a report on Thursday, July 28th. Three research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $160.79.
In other news, SVP Thomas W. Loewald sold 8,025 shares of Thermo Fisher Scientific stock in a transaction on Wednesday, July 13th. The shares were sold at an average price of $155.00, for a total transaction of $1,243,875.00. Following the transaction, the senior vice president now owns 52,194 shares in the company, valued at $8,090,070. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Marc N. Casper sold 28,797 shares of Thermo Fisher Scientific stock in a transaction on Friday, September 2nd. The stock was sold at an average price of $151.01, for a total transaction of $4,348,634.97. Following the transaction, the chief executive officer now owns 307,444 shares in the company, valued at approximately $46,427,118.44. The disclosure for this sale can be found here. Insiders own 0.52% of the company’s stock.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company is a provider of analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. The company operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).
Receive News & Ratings for Thermo Fisher Scientific Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc. and related companies with MarketBeat.com's FREE daily email newsletter.